AIM-102

DB16176InvestigationalSmall molecule

AIM-102 is under investigation in clinical trial NCT01501942 (Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma).

Formula / weight: C₁₆H₂₇N₃O₆ · 357.407 g/mol (avg)
Code names: AIM-102

Resolves to

Compound

UNII3JX85UOO24CAS551936-17-5

Structure

InChIKeyCNDMSQXUUIBFPE-VXGBXAGGSA-NSMILESN[C@H](CC1CCCCC1)C(=O)N[C@H](CCC(O)=O)C(=O)NCC(O)=O

What you can answer from here — as of December 20, 2020

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of AIM-102, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account